Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly nab-paclitaxel plus gemcitabine or carboplatin vs gemcitabine/carboplatin in first-line triple-negative metastatic breast cancer
2013-000113-20Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jun 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel in triple-negative breast cancer (TNBC) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-Free Survival (Phase 2). Started Jun 2013; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2013-000113-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000113-20.